BurstDR Stimulation for Painful Diabetic Neuropathy

Wake Forest University (WFU)

Status

Terminated

Conditions

Painful Diabetic Neuropathy

Treatments

Combination Product: SCS in combination with CMM

Study type

Observational

Funder types

Other

Identifiers

NCT05985291

23-817

IRB00104842

Details and patient eligibility

About

This study aims to demonstrate treatment outcomes of Painful Diabetic Neuropathy (PDN) patients treated with BurstDRTM Spinal Cord Dorsal Column Stimulator (SCS) along with conservative medical management per standard of care.

Full description

In this study, we aim to systematically collect real world, observational and prospective data on the safety and effectiveness of an SCS system for the management of PDN. This study will provide, to the best of our knowledge, the first clinical, real world, prospective data in treatment of PDN with an SCS system.

Enrollment

6 patients

Sex

All

Ages

22+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of lower extremity Painful Diabetic Neuropathy (PDN) with symptoms for at least a year prior to signing the consent form
PDN refractory to FDA approved medications: duloxetine, pregabalin, tapentadol, and capscaicin
Lower limb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS)
HbA1c ≤10%
BMI <45 kg/m2
Be 22 years of age or older at the time of enrollment
Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician
Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English
Be willing and capable of giving informed consent
Be willing and able to comply with study-related requirements, procedures, and scheduled visits
Have adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator
Be on a stable analgesic regimen, as determined by the Investigator, for at least 30 days prior to assessing pain intensity, and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device
Have stable neurological status measured by motor, sensory and reflex function as determined by the investigator

Exclusion criteria

Current daily opioid dosage greater than 120 mg morphine equivalents
Have an average pain intensity of ≥ 3 out of 10 cm on the VAS in the upper extremities due to diabetic neuropathy at enrollment
Have a diagnosis of a lower limb mononeuropathy (e.g., causalgia and tibial or peroneal neuropathies), have had a lower limb amputation other than toes due to diabetes, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs.
Have a current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury, as determined by the Investigator
Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure, as determined clinically by the Investigator
Be benefitting from an interventional procedure and/or surgery to treat lower limb pain (Subjects should be enrolled at least 30 days from last benefit).
Have an existing intrathecal pain pump and/or another active implantable device such as a pacemaker
Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with ProclaimTM system guidelines in the Physician's Manual
Have either a metastatic malignant neoplasm or untreated local malignant neoplasm
Have a life expectancy of less than one year
Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs
Be concomitantly participating in another clinical study
Be involved in an injury claim under current litigation
Be a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to chronic pain
Have a pending or approved worker's compensation claim
Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome, as determined by a psychologist in the last 12 months